MedSci Healthcare Holdings Limited (HKG:2415) shareholders that were waiting for something to happen have been dealt a blow with a 31% share price drop in the last month. For any long-term shareholders, the last month ends a year to forget by locking in a 81% share price decline.
Even after such a large drop in price, given about half the companies operating in Hong Kong's Healthcare Services industry have price-to-sales ratios (or "P/S") above 4.7x, you may still consider MedSci Healthcare Holdings as an attractive investment with its 2.4x P/S ratio. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.
SEHK:2415 Price to Sales Ratio vs Industry July 17th 2024
How MedSci Healthcare Holdings Has Been Performing
We'd have to say that with no tangible growth over the last year, MedSci Healthcare Holdings' revenue has been unimpressive. Perhaps the market believes the recent lacklustre revenue performance is a sign of future underperformance relative to industry peers, hurting the P/S. If not, then existing shareholders may be feeling optimistic about the future direction of the share price.
We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on MedSci Healthcare Holdings' earnings, revenue and cash flow.
Do Revenue Forecasts Match The Low P/S Ratio?
In order to justify its P/S ratio, MedSci Healthcare Holdings would need to produce sluggish growth that's trailing the industry.
Retrospectively, the last year delivered virtually the same number to the company's top line as the year before. However, a few strong years before that means that it was still able to grow revenue by an impressive 62% in total over the last three years. Accordingly, shareholders will be pleased, but also have some questions to ponder about the last 12 months.
Comparing that to the industry, which is predicted to deliver 37% growth in the next 12 months, the company's momentum is weaker, based on recent medium-term annualised revenue results.
With this in consideration, it's easy to understand why MedSci Healthcare Holdings' P/S falls short of the mark set by its industry peers. It seems most investors are expecting to see the recent limited growth rates continue into the future and are only willing to pay a reduced amount for the stock.
What Does MedSci Healthcare Holdings' P/S Mean For Investors?
MedSci Healthcare Holdings' recently weak share price has pulled its P/S back below other Healthcare Services companies. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.
As we suspected, our examination of MedSci Healthcare Holdings revealed its three-year revenue trends are contributing to its low P/S, given they look worse than current industry expectations. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. If recent medium-term revenue trends continue, it's hard to see the share price experience a reversal of fortunes anytime soon.
Before you take the next step, you should know about the 1 warning sign for MedSci Healthcare Holdings that we have uncovered.
If strong companies turning a profit tickle your fancy, then you'll want to check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
